Covered recipient · General Payments record
LINDSEY ROEKER
Allopathic & Osteopathic Physicians Internal Medicine Hematology
General Payments · PY2018–2024
$101,310.65
- Reported across 84 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Consulting Fee | $27,227.50 | 11 |
| Travel and Lodging | $450.00 | 1 |
| Food and Beverage | $165.84 | 4 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| ABBVIE INC. | $12,115.93 | 5 |
| Eli Lilly and Company | $7,104.12 | 5 |
| Acerta Pharma LLC | $4,440.00 | 2 |
| Janssen Global Services, LLC | $4,087.50 | 2 |
| Genentech USA, Inc. | $74.17 | 1 |
| BeiGene USA, Inc. | $21.62 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (16)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $2,200.00 | 04/25/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1105966226 | CMS |
| ABBVIE INC. | $15.93 | 06/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105966228 | CMS |
| ABBVIE INC. | $2,750.00 | 06/26/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1105966230 | CMS |
| ABBVIE INC. | $3,850.00 | 07/08/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1105966232 | CMS |
| ABBVIE INC. | $3,300.00 | 07/16/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1105966234 | CMS |
| AstraZeneca Pharmaceuticals LP | $2,220.00 | 01/21/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1104425111 | CMS |
| AstraZeneca Pharmaceuticals LP | $2,220.00 | 06/07/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1104778628 | CMS |
| BeiGene USA, Inc. | $21.62 | 08/02/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1120861947 | CMS |
| Eli Lilly and Company | $4,000.00 | 02/02/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1135132976 | CMS |
| Eli Lilly and Company | $1,600.00 | 05/23/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1135156163 | CMS |
| Eli Lilly and Company | $54.12 | 06/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135128590 | CMS |
| Eli Lilly and Company | $450.00 | 08/01/2024 | Travel and Lodging | Undisputed | 01/23/2026 | 1135128586 | CMS |
| Eli Lilly and Company | $1,000.00 | 12/11/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1135128588 | CMS |
| Genentech USA, Inc. | $74.17 | 06/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1133054711 | CMS |
| Janssen Global Services, LLC | $2,180.00 | 07/08/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1077591785 | CMS |
| Janssen Global Services, LLC | $1,907.50 | 10/11/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1077591819 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2021, 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.